inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 3 days before screening. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines. 4. patients having a total score ≥ 5 according to the covid-19 major symptom rating scale. 5. patients with mild covid-19, as defined in the moh temporary guidelines. presence of at least two criteria: spo2 ≥ 95% (required criterion), 37.5°с ≤ t ˂ 38°с, or respiratory rate (rr) ≤ 22 / min. absence of moderate/severe progression criteria. 6. disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration: * body temperature increase; * dry cough or cough with little phlegm; * dyspnoea; * myalgia; * fatigue; * feeling of congestion in the chest; * reduced sense of smell and / or taste. 7. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 8. consent to use reliable method of contraception throughout the study period. 9. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 3 days before screening. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines. 4. patients having a total score ≥ 5 according to the covid-19 major symptom rating scale. 5. patients with mild covid-19, as defined in the moh temporary guidelines. presence of at least two criteria: spo2 ≥ 95% (required criterion), 37.5°с ≤ t ˂ 38°с, or respiratory rate (rr) ≤ 22 / min. absence of moderate/severe progression criteria. 6. disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration: * body temperature increase; * dry cough or cough with little phlegm; * dyspnoea; * myalgia; * fatigue; * feeling of congestion in the chest; * reduced sense of smell and / or taste. 7. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 8. consent to use reliable method of contraception throughout the study period. 9. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: signed informed consent form. patients of both sexes aged 18 to 75 years inclusive. diagnosed covid-19 based on positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 3 days before screening. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines. patients having a total score ≥ 5 according to the covid-19 major symptom rating scale. patients with mild covid-19, as defined in the moh temporary guidelines. presence of at least two criteria: spo2 ≥ 95% (required criterion), 37.5°с ≤ t ˂ 38°с, or respiratory rate (rr) ≤ 22 / min. absence of moderate/severe progression criteria. disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration: body temperature increase; dry cough or cough with little phlegm; dyspnoea; myalgia; fatigue; feeling of congestion in the chest; reduced sense of smell and / or taste. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. consent to use reliable method of contraception throughout the study period. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: signed informed consent form. patients of both sexes aged 18 to 75 years inclusive. diagnosed covid-19 based on positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 3 days before screening. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines. patients having a total score ≥ 5 according to the covid-19 major symptom rating scale. patients with mild covid-19, as defined in the moh temporary guidelines. presence of at least two criteria: spo2 ≥ 95% (required criterion), 37.5°с ≤ t ˂ 38°с, or respiratory rate (rr) ≤ 22 / min. absence of moderate/severe progression criteria. disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration: body temperature increase; dry cough or cough with little phlegm; dyspnoea; myalgia; fatigue; feeling of congestion in the chest; reduced sense of smell and / or taste. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. consent to use reliable method of contraception throughout the study period. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 3 days before screening. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines. 4. patients having a total score ≥ 5 according to the covid-19 major symptom rating scale. 5. patients with mild covid-19, as defined in the moh temporary guidelines. presence of at least two criteria: spo2 ≥ 95% (required criterion), 37.5°с ≤ t ˂ 38°с, or respiratory rate (rr) ≤ 22 / min. absence of moderate/severe progression criteria. 6. disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration: - body temperature increase; - dry cough or cough with little phlegm; - dyspnoea; - myalgia; - fatigue; - feeling of congestion in the chest; - reduced sense of smell and / or taste. 7. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 8. consent to use reliable method of contraception throughout the study period. 9. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 3 days before screening. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines. 4. patients having a total score ≥ 5 according to the covid-19 major symptom rating scale. 5. patients with mild covid-19, as defined in the moh temporary guidelines. presence of at least two criteria: spo2 ≥ 95% (required criterion), 37.5°с ≤ t ˂ 38°с, or respiratory rate (rr) ≤ 22 / min. absence of moderate/severe progression criteria. 6. disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration: - body temperature increase; - dry cough or cough with little phlegm; - dyspnoea; - myalgia; - fatigue; - feeling of congestion in the chest; - reduced sense of smell and / or taste. 7. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 8. consent to use reliable method of contraception throughout the study period. 9. patients who are able to understand and comply with treatment and procedures during the study.